The axial spondyloarthritis (AxSpA) market boasts biologics representing two distinct drug classes, the blockbuster tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s Humira, Janssen’s Remicade and Simponi / Simponi Aria, and UCB’s Cimzia) and two IL-17 inhibitors (Novartis’s Cosentyx and Eli Lilly’s Taltz). The TNF-α inhibitors are the most widely prescribed biologics in AxSpA patients refractory to nonsteroidal anti-inflammatory drugs (NSAIDs). However, these agents face a competitive threat, both from the launch of cost-effective biosimilars and the growing IL-17 class, which has efficacy data that have met more-stringent clinical trial endpoints. Cimzia was approved by the FDA in 2019 for nonradiographic (nr)-AxSpA, marking the first FDA approval for that subpopulation, followed by Cosentyx and Taltz in June 2020. The impending entry of additional IL-17 inhibitors (UCB’s bimekizumab and Kyowa Hakko Kirin’s Lumicef) and the first oral targeted therapies—Jak inhibitors—for this indication (Pfizer’s Xeljanz and AbbVie’s Rinvoq) will also shift market dynamics. Questions answered:
How large is the treatable AxSpA population, and how will diagnosis / drug-treatment rates change over time?
What are interviewed experts’ insights on current treatment options for ankylosing spondylitis (AS) and nr-AxSpA? What clinical needs remain unfulfilled?
What pipeline products are the most promising, and what sales / uptake could they secure in AxSpA? What therapies of note are progressing in earlier phases?
What are the drivers and constraints in the AxSpA market, and how will the market evolve over the forecast period?
Content highlights: Geographies: United States, EU5, Japan Primary Research: ~30 country-specific interviews with thought-leading rheumatologists; Supported by survey data collected for this and other DRG research Epidemiology: Diagnosed prevalent cases of axial spondyloarthritis by country, ankylosing spondylitis and nonradiographic axial spondyloarthritis subpopulations Forecast: 10-year, annualized, drug-level sales and patient share of key axial spondyloarthritis therapies through 2029, segmented by brands/generics and epidemiological subpopulations Emerging therapies: Phase III: 4 drugs; Phase II: 1 drugs Product description: Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.